BRPI0721259C1 - composto, composição farmacêutica, uso de composto, e, processo para a fabricação de composto - Google Patents

composto, composição farmacêutica, uso de composto, e, processo para a fabricação de composto

Info

Publication number
BRPI0721259C1
BRPI0721259C1 BRPI0721259A BRPI0721259A BRPI0721259C1 BR PI0721259 C1 BRPI0721259 C1 BR PI0721259C1 BR PI0721259 A BRPI0721259 A BR PI0721259A BR PI0721259 A BRPI0721259 A BR PI0721259A BR PI0721259 C1 BRPI0721259 C1 BR PI0721259C1
Authority
BR
Brazil
Prior art keywords
compost
tyr
pharmaceutical composition
making
dpro
Prior art date
Application number
BRPI0721259A
Other languages
English (en)
Inventor
Romagnoli Barbara
Ludin Christian
Obrecht Daniel
Gombert Frank
Henze Heiko
Wim Vrijbloed Jan
Anthony Robinson John
Moehle Kerstin
Mukherjee Reshmi
J Demarco Steven
Original Assignee
Polyphor Ltd
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polyphor Ltd, Univ Zuerich filed Critical Polyphor Ltd
Publication of BRPI0721259A2 publication Critical patent/BRPI0721259A2/pt
Publication of BRPI0721259B1 publication Critical patent/BRPI0721259B1/pt
Publication of BRPI0721259B8 publication Critical patent/BRPI0721259B8/pt
Publication of BRPI0721259C1 publication Critical patent/BRPI0721259C1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Abstract

composto, composição farmacêutica, uso de composto, e, processo para a fabricação de composto. os peptidomiméticos tipo grampo de cabelo (beta) fixados sobre matriz ciclo(-tyr-his-x-cys-ser-ala-dpro-dab-arg-tyr-cys-tyr-gln-lys- pro-pro), ligação de dissulfeto entre cys4 e gys11, e sais farmaceuticamente aceitáveis destes, com x sendo ala ou tyr, têm propriedades antagonizadoras cxcr4 e podem ser usados para prevenir infecções por hiv em indivíduos saudáveis ou para diminuir e parar a progressão viral em pacientes infectados; ou onde o câncer é mediado ou resultante da atividade receptora de cxcr4; ou onde as doenças imunológicas são mediadas ou resultantes da atividade receptora de cxcr4; ou para tratar a imunossupressão; ou, em particular, para a mobilização das células tronco das células tronco do sistema periférico e/ou célula tronco mesenquimal (msc) e/ou outras células tronco cuja retenção depende do receptor de cxcr4. estes peptidomiméticos tipo grampo de cabelo (beta) podem ser fabricados através de um processo que é fundamentado em um estratégia sintética de fase sólida e de solução, usando métodos que são bem, conhecidos àqueles adequadamente habilitados na química peptídica.
BRPI0721259A 2007-02-28 2007-02-28 composto, composição farmacêutica, uso de composto, e, processo para a fabricação de composto BRPI0721259C1 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CH2007/000101 WO2008104090A1 (en) 2007-02-28 2007-02-28 Template-fixed peptidomimetics

Publications (4)

Publication Number Publication Date
BRPI0721259A2 BRPI0721259A2 (pt) 2013-01-15
BRPI0721259B1 BRPI0721259B1 (pt) 2020-04-07
BRPI0721259B8 BRPI0721259B8 (pt) 2020-09-15
BRPI0721259C1 true BRPI0721259C1 (pt) 2021-05-25

Family

ID=37891752

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0721259A BRPI0721259C1 (pt) 2007-02-28 2007-02-28 composto, composição farmacêutica, uso de composto, e, processo para a fabricação de composto

Country Status (21)

Country Link
US (7) US8399611B2 (pt)
EP (1) EP2132221B1 (pt)
JP (1) JP5140686B2 (pt)
KR (1) KR101479148B1 (pt)
CN (1) CN101641372B (pt)
AT (1) ATE475667T1 (pt)
AU (1) AU2007348171B2 (pt)
BR (1) BRPI0721259C1 (pt)
CA (1) CA2679414C (pt)
DE (1) DE602007008150D1 (pt)
DK (1) DK2132221T3 (pt)
EA (1) EA017583B1 (pt)
ES (1) ES2349879T3 (pt)
HK (1) HK1138011A1 (pt)
IL (1) IL200312A (pt)
MX (1) MX2009008843A (pt)
NO (1) NO342598B1 (pt)
NZ (1) NZ579875A (pt)
PL (1) PL2132221T3 (pt)
PT (1) PT2132221E (pt)
WO (1) WO2008104090A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007079597A1 (en) 2006-01-16 2007-07-19 Polyphor Ltd. Template - fixed peptidomimetics with antimicrobial activity
WO2008092281A1 (en) 2007-01-29 2008-08-07 Polyphor Ltd. Template-fixed peptidomimetics
AU2007348171B2 (en) 2007-02-28 2012-09-06 Polyphor Ltd. Template-fixed peptidomimetics
WO2010127704A1 (en) * 2009-05-07 2010-11-11 Polyphor Ag Beta-hairpin peptidomimetics having cxcr4 antagonizing activity
US8716242B2 (en) 2009-12-04 2014-05-06 Polyphor Ag β-hairpin peptidomimetics
US20150030561A1 (en) 2011-05-16 2015-01-29 Genzyme Corp. Use of CXCR4 Antagonists
US9079939B2 (en) * 2011-06-07 2015-07-14 Polyphor Ag Beta-hairpin peptidomimetics as CXC4 antagonists
MX349788B (es) * 2011-10-07 2017-08-11 Polyphor Ag Peptidomimeticos fijados a plantilla como inhibidores de receptor de formil-peptido 1.
JP6047231B2 (ja) * 2012-06-06 2016-12-21 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ β−ヘアピンペプチド模倣薬
HUE035891T2 (en) * 2012-08-08 2018-05-28 Polyphor Ag Combinations with ring peptides
JP7405345B2 (ja) * 2018-10-05 2023-12-26 株式会社ステムリム 間葉系幹細胞の動員活性を有するペプチド
WO2022106061A1 (en) 2020-11-19 2022-05-27 Polyphor Ag Pharmaceutical combinations comprising a peptide cxcr4 inhibitor and a taxane for treating cancer
WO2022184320A2 (en) 2021-03-03 2022-09-09 Spexis Ag Medical use of cyclic peptides
WO2023285677A1 (en) 2021-07-16 2023-01-19 Spexis Ag Pharmaceutical combinations for treating cancer
WO2023285681A1 (en) 2021-07-16 2023-01-19 Spexis Ag Pharmaceutical combinations for treating cancer

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1367789B (zh) 1999-08-30 2012-06-06 波利弗尔股份公司 模板固定的β-发夹环模拟物的合成
EP1363934B1 (en) * 2001-02-23 2014-10-08 Polyphor Ltd. Template-fixed peptidomimetics with antimicrobial activity
CN101157924A (zh) 2001-12-11 2008-04-09 人体基因组科学有限公司 嗜中性白细胞因子α
AU2003202914A1 (en) * 2002-01-07 2003-07-24 Sequoia Pharmaceuticals Broad spectrum inhibitors
EP1532164B1 (en) 2002-08-20 2012-09-26 Polyphor Ltd. Template-fixed peptidomimetics with antibacterial activity
US7855179B2 (en) 2002-10-02 2010-12-21 Polyphor Ltd. Template-fixed peptidomimetics with antimicrobial activity
WO2004096839A1 (en) 2003-05-02 2004-11-11 Polyphor Ag Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity
US7838496B2 (en) 2003-05-02 2010-11-23 Polyphor Ag/Ltd. Template-fixed peptidomimetics as medicaments against HIV and cancer
US7681235B2 (en) 2003-05-19 2010-03-16 Radware Ltd. Dynamic network protection
WO2005047503A1 (en) 2003-11-15 2005-05-26 Polyphor Ltd. Template fixed βετα-hairpin loop mimetics and their use in phage display
WO2006087001A1 (en) 2005-02-17 2006-08-24 Polyphor Ltd. Template-fixed beta-hairpin peptidomimetics with protease inhibitory activity
ATE520705T1 (de) 2005-05-02 2011-09-15 Polyphor Ltd Farbstoffkonjugate von schablonenfixierten peptidomimetika
WO2007079597A1 (en) 2006-01-16 2007-07-19 Polyphor Ltd. Template - fixed peptidomimetics with antimicrobial activity
WO2008092281A1 (en) 2007-01-29 2008-08-07 Polyphor Ltd. Template-fixed peptidomimetics
AU2007348171B2 (en) 2007-02-28 2012-09-06 Polyphor Ltd. Template-fixed peptidomimetics
CA2733117C (en) 2008-08-08 2016-03-22 Polyphor Ag Template-fixed peptidomimetics
US8883720B2 (en) 2008-11-26 2014-11-11 Polyphor Ag Template-fixed beta-hairpin peptidomimetics with CXCR4 antagonizing activity
WO2010127704A1 (en) 2009-05-07 2010-11-11 Polyphor Ag Beta-hairpin peptidomimetics having cxcr4 antagonizing activity
JP5727479B2 (ja) 2009-08-05 2015-06-03 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ コンホメーションを固定された、合成マクロ環化合物
WO2011060832A1 (en) 2009-11-20 2011-05-26 Polyphor Ag Template-fixed peptidomimetics with ccr10 antagonistic activity
US8716242B2 (en) 2009-12-04 2014-05-06 Polyphor Ag β-hairpin peptidomimetics
WO2011095220A1 (en) 2010-02-05 2011-08-11 Polyphor Ag Template - fixed peptidomimetics with cxcr7 modulating activity
WO2011095218A1 (en) 2010-02-05 2011-08-11 Polyphor Ag Template-fixed pep tidomime tics with cxcr7 modulating activity
US8895499B2 (en) 2010-08-05 2014-11-25 Polyphor Ag β-hairpin peptidomimetics
US9079939B2 (en) 2011-06-07 2015-07-14 Polyphor Ag Beta-hairpin peptidomimetics as CXC4 antagonists
MX349788B (es) 2011-10-07 2017-08-11 Polyphor Ag Peptidomimeticos fijados a plantilla como inhibidores de receptor de formil-peptido 1.
US10017481B2 (en) 2012-03-17 2018-07-10 Polyphor Ag Conformationally constrained, fully synthetic macrocyclic compounds
JP6047231B2 (ja) 2012-06-06 2016-12-21 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ β−ヘアピンペプチド模倣薬
HUE035891T2 (en) 2012-08-08 2018-05-28 Polyphor Ag Combinations with ring peptides
KR102142870B1 (ko) 2012-08-08 2020-08-11 폴리포 리미티드 백본-고리형 펩타이드와의 조합물
KR102279427B1 (ko) 2013-03-30 2021-07-20 폴리포 리미티드 Beta-헤어핀 펩타이드 모방체
EA034926B1 (ru) 2013-03-30 2020-04-07 Полифор Аг Бета-шпилечные пептидомиметики
EP3087087B1 (en) 2013-12-27 2021-07-21 Polyphor Ag Beta-hairpin peptidomimetics as selective elastase inhibitors
JP6499183B2 (ja) 2013-12-27 2019-04-10 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ 選択的エラスターゼ阻害剤としてのβ−ヘアピンペプチド模倣体

Also Published As

Publication number Publication date
NO20093064L (no) 2009-09-28
NZ579875A (en) 2012-02-24
ATE475667T1 (de) 2010-08-15
US10144765B2 (en) 2018-12-04
EP2132221A1 (en) 2009-12-16
US20130150299A1 (en) 2013-06-13
US11421001B2 (en) 2022-08-23
EP2132221B1 (en) 2010-07-28
BRPI0721259B8 (pt) 2020-09-15
BRPI0721259B1 (pt) 2020-04-07
US9879047B2 (en) 2018-01-30
CN101641372B (zh) 2012-11-28
CA2679414A1 (en) 2008-09-04
US20200399317A1 (en) 2020-12-24
IL200312A (en) 2014-11-30
PL2132221T3 (pl) 2011-04-29
WO2008104090A1 (en) 2008-09-04
PT2132221E (pt) 2010-10-26
AU2007348171A1 (en) 2008-09-04
IL200312A0 (en) 2010-04-29
US20150080317A1 (en) 2015-03-19
CN101641372A (zh) 2010-02-03
DK2132221T3 (da) 2010-11-22
US8921325B2 (en) 2014-12-30
US20100048463A1 (en) 2010-02-25
JP5140686B2 (ja) 2013-02-06
KR20100014596A (ko) 2010-02-10
US10787486B2 (en) 2020-09-29
NO342598B1 (no) 2018-06-18
US9556234B2 (en) 2017-01-31
US20170096453A1 (en) 2017-04-06
US8399611B2 (en) 2013-03-19
BRPI0721259A2 (pt) 2013-01-15
US20190100558A1 (en) 2019-04-04
AU2007348171B2 (en) 2012-09-06
ES2349879T3 (es) 2011-01-12
EA200901178A1 (ru) 2010-04-30
US20180127467A1 (en) 2018-05-10
DE602007008150D1 (de) 2010-09-09
HK1138011A1 (en) 2010-08-13
EA017583B1 (ru) 2013-01-30
JP2010519331A (ja) 2010-06-03
KR101479148B1 (ko) 2015-01-05
CA2679414C (en) 2014-10-28
MX2009008843A (es) 2009-08-28

Similar Documents

Publication Publication Date Title
BRPI0721259B8 (pt) composto, composição farmacêutica, uso de composto, e, processo para a fabricação de composto
BRPI0720551A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo
CO6761350A2 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
CL2012000623A1 (es) Compuestos derivados de 4-[4,4-dimetil-5oxo-3-(piridin-ilmetil)-2-tioxoimidazolidin-1-il]-2-(trifluorometil)benzonitrilo, con propiedades antiandrogenicas; metodo de preparacion; composcion farmaceutica; y su uso para el tratamiento y/o profilaxis de cancer de prostata.
CL2003002731A1 (es) Compuesto derivado de quinazolina de formula definida, que actua como inhibidor de la kinasa aurora; procedimiento de preparacion del compuesto; composicion farmaceutica que comprende al compuesto y uso del compuesto; util para el tratamiento de enfe
WO2007022257A3 (en) Monocyclic and bicyclic compounds and methods of use
PE20140382A1 (es) Polipeptidos derivados de la il-2 con actividad agonista para la terapia del cancer e infecciones cronicas
CL2012002497A1 (es) Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras.
CL2011002056A1 (es) Compuestos derivados del acido {7-([1,2,3]triazol-1-il)-6,7,8,9-tetrahidropirido[1,2-a]indol-10-il}-acetico, antagonista del receptor crth2; composicion farmaceutica que lo comprende; utiles ene l tratamiento del asma, alergias, cancer entre otras.
CL2008003593A1 (es) Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer
BR112012021337A2 (pt) formulações de apixaban.
MX2009003129A (es) Derivados de oxadiazol con propiedades anti-inflamatorias e inmunosupresoras.
CL2011003266A1 (es) Compuestos derivados de imidazolidin-2-ona, con actividad inhibidora de 17alfa-hidroxilasa/liasa-c17,20; composicion farmaceutica que los comprende; y uso en el tratamiento de inflamacion o cancer, entre otras.
WO2010068287A8 (en) Small molecule modulators of hepatocyte growth factor (scatter factor) activity
EP3744340A3 (en) Compositions and methods for treating cancer
WO2007044804A3 (en) Piperidine derivatives and methods of use
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
MX2019013801A (es) Compuestos de citocina inhibidora de macrofagos-1 (mic-1) y usos de estos.
WO2008103378A3 (en) Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
WO2009018226A3 (en) Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (cd49e)
ZA200807027B (en) Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
MX2021004883A (es) Metodos y composiciones para tratar apnea del sue?o.
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/04/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2570 DE 07/04/2020 QUANTO AO INVENTOR.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/02/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B22B Petition not considered [chapter 22.2 patent gazette]

Free format text: NAO CONHECIDA A PETICAO NO 870210067284, DE 23/07/2021, EM VIRTUDE DO DISPOSTO NO ART. 219 , INCISO II DA LPI